Trump Weighs Government Equity in AI Firms for Public Fund

President Donald Trump announced last week that he plans to meet with executives from leading artificial intelligence companies to explore a financial partnership in which the federal government could take ownership stakes in major AI firms and distribute returns to the public. The idea, first pitched to Trump by OpenAI chief Sam Altman in early 2025, has gained traction in recent White House discussions, according to reporting from NOTUS. Trump described the arrangement as one in which “pieces of these companies could be given to the American public,” positioning everyday citizens as partners who would benefit from AI profits through mechanisms such as universal dividends.

The proposal arrives amid broader conversations about how AI-driven automation could widen economic inequality. Proponents argue that a well-structured public wealth fund might capture a portion of the technology’s gains and redistribute them, echoing models used in places like Norway’s sovereign wealth fund. Yet the version under discussion appears informal and voluntary, with top labs potentially donating shares directly to the government rather than through legislation or transparent oversight. This approach raises immediate questions about accountability and favoritism.

Critics note that Altman and other AI leaders have strong incentives to align their companies with administration priorities. An ownership stake could shield participating firms from aggressive regulation or antitrust scrutiny by tying government revenue to their success. Such an arrangement risks creating a narrow circle of favored companies rather than genuine public control over productive assets. Without clear rules on governance, valuation, or profit-sharing, the deal could function more as corporate welfare than a serious effort to address wealth concentration.

The timing coincides with a separate push by AI executives on safety policy. Altman, along with Demis Hassabis of Google DeepMind and Dario Amodei of Anthropic, recently joined dozens of experts in signing an open letter urging stricter controls on gene synthesis technology. The letter highlights risks that advanced AI systems could assist in designing custom DNA sequences for biological weapons. Gene synthesis already enables valuable medical and agricultural advances, yet the same tools could lower barriers for malicious actors if left unregulated.

Industry alignment on this issue stands out given the companies’ fierce competition over model development and market share. Coordinated calls for oversight often serve dual purposes: addressing legitimate public safety concerns while shaping rules that established players can more easily meet. When paired with the proposed equity partnership, the pattern suggests AI firms are actively courting influence across both economic and regulatory fronts.

Trump’s history of deal-making with business leaders offers little reassurance that the AI talks will prioritize broad public benefit. Past administration actions frequently rewarded politically connected companies with tax breaks and relaxed enforcement rather than structural reforms. An ad-hoc equity arrangement negotiated behind closed doors would likely follow the same pattern, concentrating benefits among a handful of Silicon Valley firms while offering symbolic gestures to the wider public.

Any serious effort to give Americans a stake in AI would require legislation establishing independent management, transparent accounting, and protections against political interference. Voluntary share donations arranged through the White House fall far short of that standard. They instead point toward a familiar outcome in which corporate interests secure government backing under the banner of shared prosperity.